
Our Preferred Partners
Contract research organizations (CROs), distributors and technologies that have created validated assays with Anatomic hiPSC-derived cell types.
Neuroservices-Alliance
Neuroservices-Alliance is a global provider of state-of-the-art neuro-pharmacological functional endpoints, helping pharmaceutical companies accelerate their CNS and Pain drug discovery programs. Neuroservices-Alliance is Anatomic's preferred partner for neuropharmacology and electrophysiology studies utilizing manual patch clamp, calcium imaging and HD-MEA. They have already conducted several successful studies for clients utilizing RealDRG, demonstrating their effectiveness and reliability in a number of assays.
For more information, click here to learn more about their capabilities focused on electrophysiology and optophysiology recordings of DRG sensory neurons or view our collaborative SfN2023 poster.
Nanion Technologies
We are proud to partner with Nanion, a leader in providing trusted scientific support and exceptional instrumentation to advance drug development and scientific discoveries. Nanion offers a broad range of applications and user-friendly assay solutions that can be tailored to meet your research needs, enhancing and improving your projects.
Anatomic and Nanion have collaborated over the years to generate a high-throughput assay for functionally testing a number of ion channel targets in RealDRG hiPSC-derived sensory neurons. For more information about Nanion's capabilities and how they can enhance your research, click here.

VitroVo
VitroVo offers a wide range of electrophysiological assays on various in vitro neural networks, brain organoids, acute brain slices, and cardiomyocytes using numerous micro-electrode array (MEA) technologies. VitroVo has experience co-culturing RealDRG hiPSC-derived sensory neurons and RealDHN hiPSC-derived dorsal horn neurons for functional studies. For more information, click here to learn more about their capabilities.

Medicines Discovery Catapult
Medicines Discovery Catapult (MDC) is a national Life Sciences service dedicated to turning drug discovery into commercial breakthroughs. At the frontier of drug discovery, MDC works with entrepreneurial scientists to make every move count. It validates their ideas, de-risks investments, and feeds insights back into the sector to drive productivity and impact.​ MDC creates momentum through its unique blend of discovery expertise, technology, insights, and sector-leading partnerships. Where there is unmet patient need, MDC stimulates innovation through its National Programmes. ​MDC has helped over 300 companies raise more than £1.2bn of R&D investment. ​Its approach to drug discovery drives game-changing breakthroughs and improves
patients’ lives.​
NETRI
NETRI is a pioneering provider of organ-on-chip technologies designed to accelerate drug discovery through scalable, human-relevant in vitro models. Their DuaLink™ microfluidic MEA platform enables real-time electrophysiological and functional readouts in complex neuromuscular systems, opening new possibilities for efficacy and toxicity testing. Anatomic is proud to partner with NETRI to advance next-generation NMJ disease models. By combining NETRI’s DuaLink platform with Anatomic’s hiPSC-derived motor neurons, researchers can model neuromuscular junction formation and degeneration in a compartmentalized, MEA-compatible system. Together, NETRI and Anatomic offer a translational solution for studying ALS and other neuromuscular diseases at scale. View our collaborative poster to learn more.






